-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $85

Benzinga·09/09/2026 13:12:14
Listen to the news
Barclays analyst Eliana Merle maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $90 to $85.